Carr-Brendel will replace Jan Keltjens, who served as interim CEO of the transcatheter aortic valve repair-focused company since January 2015. Keltjens will remain with the company as chairman of the board, JenaValve said.
In January, Keltjens replaced retiring medical device vet David Drachman as CEO, who previously spent 10 years at AtriCure (NSDQ:ATRC).
“Given JenaValve’s unique pericardial tissue valve and new transapical and transfemoral delivery systems, the company is poised to become a leader in transcatheter aortic valve repair. JenaValve is an innovative, nimble company that holds promise to make a significant impact in this competitive, growing market. I am confident that my product development expertise and experience in the commercialization of complex cardiovascular products are a perfect fit as we launch our new TAVI system worldwide. It is my intention to lead JenaValve to achieve the promise that the investors and employees have worked at over the past years for patients in need,” Carr-Brendel said in a press release.
“With an impressive background and proven leadership in the medical device sector, Dr. Carr-Brendel is ideally qualified to lead JenaValve through its next phase of growth and position JenaValve as an important player in the large and rapidly growing worldwide TAVR market. Our global team has worked diligently over the past several months to complete the design of our new pericardial tissue valve and transfemoral delivery system, and we will continue clinical work soon to support regulatory approval,” Keltjens said in a prepared statement.
Longtime Abiomed CFO Brown retires
Abiomed (NSDQ:ABMD) said long-time CFO and vice president Robert Bowen is due to retire next month, with former Cubist Pharmaceuticals CFO Michael Tomsicek tapped to take his place.
Ex-CareFusion exec Frantz lands CEO spot at Quality Systems
Quality Systems tapped ex-CareFusion executive Rusty Frantz as its new CEO, replacing 7-year chief executive Steven Plochocki, who is retiring.